Citadel Advisors
XERS icon

Citadel Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Citadel Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.26M Sell
664,564
-17,070
-3% -$109K ﹤0.01% 4627
2026
Q1 		$3.95M Buy
681,634
+271,814
+66% +$1.8M ﹤0.01% 4732
2025
Q4 		$3.22M Sell
409,820
-27,792
-6% -$219K ﹤0.01% 5045
2025
Q3 		$3.56M Buy
+437,612
New +$2.91M ﹤0.01% 4978
2025
Q2 		– Sell
-1,347,859
Closed -$6.18M – 15390
2025
Q1 		$7.4M Buy
1,347,859
+514,531
+62% +$2.08M ﹤0.01% 3287
2024
Q4 		$2.82M Buy
+833,328
New +$2.68M ﹤0.01% 4938
2024
Q2 		– Sell
-95,348
Closed -$192K – 15559
2024
Q1 		$211K Sell
95,348
-305,229
-76% -$790K ﹤0.01% 10203
2023
Q4 		$941K Buy
400,577
+371,383
+1,272% +$685K ﹤0.01% 6795
2023
Q3 		$54.3K Buy
+29,194
New +$66.9K ﹤0.01% 11665
2023
Q1 		– Sell
-21,240
Closed -$26.6K – 15609
2022
Q4 		$28.2K Sell
21,240
-14,910
-41% -$21K ﹤0.01% 12807
2022
Q3 		$57K Sell
36,150
-52,173
-59% -$86.3K ﹤0.01% 11535
2022
Q2 		$136K Sell
88,323
-54,891
-38% -$116K ﹤0.01% 11082
2022
Q1 		$366K Buy
143,214
+28,867
+25% +$70.5K ﹤0.01% 10134
2021
Q4 		$335K Buy
114,347
+38,513
+51% +$83.2K ﹤0.01% 10684
2021
Q3 		$186K Buy
75,834
+1,592
+2% +$4.62K ﹤0.01% 12091
2021
Q2 		$302K Sell
74,242
-33,820
-31% -$129K ﹤0.01% 11261
2021
Q1 		$487K Buy
108,062
+49,265
+84% +$266K ﹤0.01% 9736
2020
Q4 		$289K Buy
58,797
+35,391
+151% +$177K ﹤0.01% 9145
2020
Q3 		$139K Sell
23,406
-8,982
-28% -$35.9K ﹤0.01% 9052
2020
Q2 		$86K Buy
+32,388
New +$113K ﹤0.01% 9077
2019
Q2 		– Sell
-29,941
Closed -$301K – 9955
2019
Q1 		$301K Buy
+29,941
New +$384K ﹤0.01% 7608
2018
Q3 		– Sell
-11,290
Closed -$214K – 9760
2018
Q2 		$214K Buy
+11,290
New +$219K ﹤0.01% 7782

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors's XERS Position: Q2 2026 in Review

Citadel Advisors reduced its Xeris Biopharma Holdings (XERS) stake by 2.5% in Q2 2026, selling an estimated $109K and leaving 664,564 shares worth $5.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4627.

Citadel Advisors first reported a position in XERS in Q2 2018 and has held it in 22 quarters since. The position peaked at $7.4M in Q1 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Citadel Advisors held 664,564 shares of Xeris Biopharma Holdings worth $5.26M as of Q2 2026.
  • Citadel Advisors sold 17,070 Xeris Biopharma Holdings shares in Q2 2026, an estimated $109K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4627 holding.
  • Citadel Advisors first reported a position in Xeris Biopharma Holdings in Q2 2018 and has held it in 22 quarters since.
  • Citadel Advisors's Xeris Biopharma Holdings position peaked at $7.4M in Q1 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.